Vitamins & Nutrition · LP-173
Thiamine (Vitamin B1) Tablets
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-173Vitamins & Nutrition
- Generic identity
- Thiamine (Vitamin B1)Tablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-173
- Generic ingredient
- Thiamine (Vitamin B1)
- Dosage form
- Tablet
- Proposed strength
- 100 mg
- Proposed pack
- Blister/bottle
- Portfolio category
- Vitamins & Nutrition
About Thiamine (Vitamin B1)
Thiamine is vitamin B1, an essential nutrient involved in carbohydrate metabolism and normal neurological and cardiac function. Deficiency can have serious consequences and occurs in different nutritional and medical settings. Oral and injectable thiamine serve different purposes depending on urgency, absorption and the clinical condition. An oral tablet should not be assumed to substitute for parenteral treatment when an acute deficiency syndrome is suspected.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Assessment can involve poor nutritional intake, malabsorption or other circumstances associated with deficiency. Acute neurological symptoms in a person at risk require urgent medical evaluation rather than reliance on a supplement catalogue. A clinician determines whether oral or parenteral treatment is appropriate and whether associated nutritional or electrolyte problems need attention. This page does not provide an emergency protocol or confirm a locally authorized indication for the proposed presentation.
Important safety considerations
Thiamine is often well tolerated, but hypersensitivity can occur. Parenteral administration can rarely produce serious allergic reactions and requires an appropriate monitored setting with trained staff. Local injection reactions are possible. Persistent neurological or cardiovascular symptoms require evaluation even if thiamine has been given. The product-specific excipients and route must be checked, especially in vulnerable patients or anyone with previous reactions to injectable vitamin preparations.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
This record concerns oral thiamine tablets only. Confirm the thiamine salt, tablet coating or scoring, excipients and exact pack mapping from controlled product documentation. Injectable thiamine route, preservative, compatibility and administration controls belong to the separate LP-203 injection record.
Keep the medicine in the labelled original pack with its leaflet. Check the expiry date and pack integrity before dispensing. The authorized label must determine storage temperature, protection from moisture or light, and disposal; no shelf life or in-use period can be established from a catalogue entry.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Assess clinical urgency, nutritional history, neurological findings and the appropriate route. Verify the actual product and any monitoring requirements under relevant local guidance.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Thiamine (Vitamin B1)
- Dosage form / presentation
- Tablet
- Catalogue strength
- 100 mg
- Catalogue pack
- Blister/bottle
- Portfolio category
- Vitamins & Nutrition
Layer 02
Unresolved product-specific fields
- P027 editorial correction: the inherited injectable-excipient note was removed. LP-173 is a 100 mg thiamine tablet record and is reviewed only as an oral tablet presentation.
- Exact thiamine salt, tablet coating/scoring and excipients remain product-specific; injectable thiamine controls belong to LP-203.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- NIH ODS: Thiamin — Health Professional Fact Sheetgovernment scientific fact sheet
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled product master/specification confirming exact active chemical form, dosage form, strength variant and pack mapping.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-173, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-173.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.